Article Text

other Versions

PDF
Efficacy and tolerability of anti-TNF therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group Register
  1. Lars Erik Kristensen (larserik_kristensen{at}yahoo.com)
  1. Department of Rheumatology Lund University Hospital, Sweden
    1. Anders Gülfe (anders.gulfe{at}med.lu.se)
    1. Department of Rheumatology Lund University Hospital, Sweden
      1. Tore Saxne (tore.saxne{at}med.lu.se)
      1. Department of Rheumatology Lund University Hospital, Sweden
        1. Pierre Geborek (pierre.geborek{at}med.lu.se)
        1. Department of Rheumatology Lund University Hospital, Sweden

          Abstract

          Background: The use of TNF blocking agents in psoriatic arthritis (PsA) is increasing, and the SSATG register has followed patients with PsA for more than 5 years.

          Objective: To present efficacy and tolerability data of TNF-blocking agents on PsA in clinical practice. Also to study potential predictors for drug survival. Material and Methods: Patients (n=261) with active PsA, starting anti-TNF therapy for the first time in southern Sweden, were included. Basal characteristics, disease activity measures, and termination reason for TNF-blockers were prospectively collected during the period April 1999 to September 2006. Cox proportional hazard models were used to investigate predictors for treatment termination.

          Results: Overall, response rates at 3-12 months for VASglobal50 and VASpain50 were about 50%, whereas response rates for EULAR overall and EULAR good were around 75% and 55%, respectively. Concomitant MTX (HR=0.64 (95% CI 0.39-0.95), p=0.03), etanercept (HR=0.49 (0.28-0.86), p=0.01), and high CRP-levels (HR=0.77 (0.61-0.97), p=0.03) at treatment initiation were associated with better overall drug survival. The improved drug survival of concomitant MTX appeared to be related to significantly fewer drop outs because of adverse events (HR= 0.24 (0.11-0.52), p<0.01). The TNF-blockers were well tolerated with a rate of serious adverse events of 5-6% per year. No unexpected serious adverse events were observed.

          Conclusion: Concomitant MTX and high CRP-levels are associated with treatment continuation of anti-TNF therapy in patients with PsA regardless of joint distribution. The positive effect of MTX was primarily linked to fewer drop outs because of adverse events.

          • TNF blockers
          • biologics register
          • methotrexate
          • psoriatic arthritis

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.